Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled randomized trial of baxdrostat for uncontrolled hypertension on at least two antihypertensive drugs, including resistant hypertension
MOH_2023-09-20_012951Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baxdrostat in hypertension (HTN) and resistant hypertension (RH) (3 arms), sponsored by AstraZeneca. Started Sep 2023; status: recruiting.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on MOH_2023-09-20_012951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-20_012951.